KOrean Borderline Ovarian Tumor (KOBOT) Registry
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Ovarian Neoplasms. Basic parameters: No limits · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- South Korea
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Establishing the Registry of Korean Patients With Borderline Ovarian Tumors
Overview
The aim of this study is to collect data on Korean patients with borderline ovarian tumors.
Detailed description
The researchers retrospectively collected data on Korean patients with borderline ovarian tumors (BOTs) diagnosed, treated, and followed between November 1994 and February 2015 at institutions where placed in the Republic of Korea. And the researchers prospectively will collect data on all Korean patients with BOTs at institutions where placed in the Republic of Korea since March, 2015. If patients agree to participate in this KOBOT registry, patient's data (such as age, body mass index, preoperative findings, laboratory findings, radiologic findings, operative findings, pathologic findings, postoperative findings) will be collected in a research database. The research database will be updated, every 6 month, to include data on patient's disease outcome and follow-up care. Although most data will be collected form the medical record, patient may agin be contacted so that researchers can collection some data if it is not in the medical record.
Primary outcome measures
- Recurrence-free survival [Time frame: up to 100 months]
Eligibility criteria
Inclusion criteria
- Patients with borderline ovarian tumors (BOTs) diagnosed, treated, and followed between November 1994 and February 2015 at institutions where placed in the Republic of Korea.
- All patients undergoing gynecologic surgery for BOTs at institutions where placed in the Republic of Korea since March, 2015
Exclusion criteria
- Patients who did not receive primary treatment or follow-up for at least 6 months at each institution were excluded from analysis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
South Korea · 4 centers
- Samsung Changwon Hospital — Changwon
- Kangbuk Samsung Hospital — Seoul
- CHA Gangnam Medical Center — Seoul
- Samsung Medical Center — Seoul
Identifiers
NCT: NCT02803970 · 2015-08-002